Axa’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Axa’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-57,035	Closed	-$518K	–	1452
2018 Q1	$518K	Buy	57,035 +33,535	+143%	+$185K	﹤0.01%	1152
2017 Q4	$101K	Buy	+23,500	New	+$112K	﹤0.01%	1327
2016 Q1	–	Sell	-64,001	Closed	-$257K	–	1476
2015 Q4	$257K	Sell	64,001 -25,040	-28%	-$115K	﹤0.01%	1142
2015 Q3	$408K	Buy	+89,041	New	+$466K	﹤0.01%	1086
2015 Q1	–	Sell	-28,100	Closed	-$177K	–	1516
2014 Q4	$177K	Buy	+28,100	New	+$171K	﹤0.01%	1275

Other funds holding ECYT

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Axa's ECYT Position: Q2 2018 in Review

Axa sold out of Endocyte, Inc. Common Stock (ECYT) in Q2 2018, closing a stake of 57,035 shares — an estimated $518K sold.

Axa first reported a position in ECYT in Q4 2014 and held it in 5 quarters. The position peaked at $518K in Q1 2018. 114 funds tracked by Wall St. Rank hold ECYT as of Q2 2018.

Axa reported no remaining Endocyte, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
Axa sold 57,035 Endocyte, Inc. Common Stock shares in Q2 2018, an estimated $518K.
Axa first reported a position in Endocyte, Inc. Common Stock in Q4 2014 and held it in 5 quarters.
Axa's Endocyte, Inc. Common Stock position peaked at $518K in Q1 2018.
114 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q2 2018.

Based on Axa's 13F filing for Q2 2018, filed 13 Aug 2018.